KKR and Impilo Complete Joint Acquisition of Immedica Pharma

Strategic Insights -

KKR and Impilo have jointly acquired Immedica Pharma, a Stockholm-based pharmaceutical company focused on commercializing medicines for rare diseases and specialty care products. The acquisition supports Immedica's growth in the European rare disease space, with KKR and Impilo working together with the company's management team to drive business expansion. Immedica has built a portfolio and pipeline of drugs for rare conditions, generating EUR 100m in revenues and annual growth of over 50% since its founding in 2018.

Key Takeaways:

  • KKR and Impilo have completed a joint acquisition of Immedica Pharma, a pharmaceutical company focused on commercializing medicines for rare diseases and specialty care products.
  • Immedica's management team will work with KKR and Impilo to support business growth in the European rare disease space.
  • Immedica has generated EUR 100m in revenues and annual growth of over 50% since its founding in 2018.
  • KKR invested in Immedica through its KKR Health Care Strategic Growth Fund II, a $4.0 billion fund focused on investing in high-growth health care companies.
  • Impilo re-invested into Immedica through a continuation fund, enabling the investment firm to continue supporting Immedica with additional equity alongside KKR.
  • KKR has a long track record of supporting health care companies globally, having invested approximately $20 billion in the sector since 2004.
  • Immedica is a pharmaceutical company headquartered in Stockholm, Sweden, with a global distribution network serving patients in more than 50 countries.

Statistics:

  • EUR 100m: Immedica's revenue generated since its founding in 2018.
  • 50%: Immedica's annual growth rate since its founding in 2018.
  • $20 billion: KKR's approximately total investment in the health care sector since 2004.
  • EUR 1 billion: Impilo's managed capital from leading Nordic and international investors.
  • 2018: Immedica's founding year.

Sources:

  • KKR's press release regarding the joint acquisition of Immedica Pharma.
  • Global Atlantic Financial Group's website at www.globalatlantic.com.
  • Impilo's website at www.impilo.se.
  • Immedica's website and press release.